Skip to main content
SpringerLink
Log in

Synthesis and in vivo studies of a specific monoamine oxidase B inhibitor: 5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)-1,3,4-oxadiazol-[11C]-2(3H)-one

Biodistribution in the rat and positron emission tomography studies in the baboon brain

  • Original article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

We report the radiochemical synthesis of a specific MAO B inhibitor, namely 5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)-1,3,4-oxadiazol-[11C]-2(3H)-one (2b) (in vitro IC50=4nM and selectivity over 71000 for MAO B), by cyclization of its hydrazide precursor1 with [11C]phosgene. The reaction occurred within 2 min. The product obtained after HPLC purification,2b, had a high specific activity (11.1–22.2 GBq/µmol), allowing its use in experiments as a radiotracer in vivo. Biodistribution of2b in the CNS and in the peripheral organs of the rat, and positron emission tomography (PET) studies in the living baboon brain, pretreated or not withl-deprenyl (1 mg/kg, 1 h), an irreversible MAO B-specific inhibitor, were undertaken. The results showed a good uptake of2b in all organs of the rat, with a rapid clearance from the blood (10 min). Metabolite analyses in plasma and in the diencephalon of the rat showed that2b was the only radioactive compound in brain structure whereas in plasma three other radioactive products appeared. PET experiments show that in thel-deprenyl-pretreated baboon brain, specific binding of2b represents around 70% of total radioactivity, whereas in the blood and plasma the radioactivity cleared rapidly (15 min).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue.Biochem Pharmacol 1968; 17: 1285–1297.

    Google Scholar 

  2. Bach AWJ, Lan NC, Johnson DL, Abell CW, Bambenek ME, Kwan SW, Seeburg PH, Shih JC. cDNA cloning of human liver monoamine oxidase A and B: molecular bases of differences in enzymatic properties.Proc Natl Acad Sci USA 1988; 85: 4934–4938.

    Google Scholar 

  3. Hsu Y-PP, Weyler W, Chen S, Sims KB, Rinehart WB, Utterback MC, Powell JF, Breakefield XO. Structural features of human monoamine oxidase A elucidated from cDNA and peptide sequences.J Neurochem 1988; 51: 1321–1324.

    Google Scholar 

  4. Pintar JE, Barbosa J, Francke U, Castiglione CM, Hawkins M Jr, Breakefield XO. Gene for monoamine oxidase type A assigned to the human X chromosome.J Neurosci 1981; 1: 166–175.

    Google Scholar 

  5. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease.N Engl J Med 1989; 321: 1364–1371.

    Google Scholar 

  6. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.Science 1989; 245: 519–522.

    Google Scholar 

  7. Arnett CD, Fowler JS, MacGregor RR, Schlyer DJ, Wolf AP, Långström B, Halldin C. Turnovers of brain monoamine oxidase measured in vivo by positron emission tomography usingl-[11C]deprenyl.J Neurochem 1987; 49: 522–527.

    Google Scholar 

  8. Fowler JS, MacGregor RR, Wolf AP, Arnett CD, Dewey SL, Schlyer DJ, Christman D, Logan J, Smith M, Sachs H, Aquilonius SM, Bjurling P, Halldin C, Hartvig P, Leenders KL, Lundqvist H, Oreland L, Stålnacke C-G, Långström B. Mapping human brain monoamine oxidase A and B with11C-labelled suicide inactivators and PET.Science 1987; 235: 481–485.

    Google Scholar 

  9. Bench CJ, Price GW, Lammertsma AA, Luthra JC, Turton D, Dolan RJ, Kettler R, Dingemanse J, Da Prada M, Biziere K, McClelland GR, Jamienson VL, Wood ND, Frackowiak RSJ. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327.Eur J Clin Pharmacol 1991; 40: 169–173.

    Google Scholar 

  10. Lammerstma AA, Bench CJ, Price GW, Cremer JE, Luthra SK, Turton D, Wood ND, Frackowiak RSJ. Measurement of cerebral monoamine oxidase B activity usingl-[11C]-deprenyl and dynamic positron emission tomography.J Cereb Blood Flow Metab 1991; 11: 545–556.

    Google Scholar 

  11. Fowler JS, Volkow ND, Logan J, Schlyer DJ, MacGregor RR, Wang G-J, Wolf AP, Pappas N, Axeloff D, Shea C, Gatley SJ, Dorflinger E, Yoo K, Morawsky L, Fazzini E. Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19-6327.Neurology 1993; 43: 1984–1992.

    Google Scholar 

  12. Fowler JS, Volkow ND, Logan J, Wang GJ, MacGregor RR, Schlyer DJ, Wolf AP, Pappas N, Alexoff D, Shea C, Dorflinger E, Kruchowy L, Yoo K, Fazzini E, Patlak C. Slow recovery of human brain MAO B afterl-deprenyl (selegeline) withdrawal.Synapse 1994; 18: 86–93.

    Google Scholar 

  13. Fowler JS, Wolf AP, MacGregor RR, Dewey SL, Logan J, Schlyer DJ, Långström B. Mechanistic positron emission tomography studies: demonstration of a deuterium isotope effect in the monoamine oxidase-catalyzed binding of [11C]l-deprenyl in living baboon brain.J Neurochem 1988; 51: 1524–1534.

    Google Scholar 

  14. Plenevaux A, Dewey SL, Fowler JS, Guillaume M, Wolf AP. Synthesis of (R)-(−)- and (S)-(+)-4-fluorodeprenyl and (R)-(−)-and (S)-(+)-[N-11C-methyl]-4-fluorodeprenyl and positron emission tomography studies in baboon brain.J Med Chem 1990; 33: 2015–2019.

    Google Scholar 

  15. Mazouz F, Gueddari S, Burstein C, Mansuy D, Milcent R. 5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)-1,3,4-oxadiazol-(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monoamine oxidase type B inhibitors.J Med Chem 1993; 36: 1157–1167.

    Google Scholar 

  16. Synthélabo-Delalande, European Patent No. 0348257, 27.12.1989.

  17. Mazouz F, Lebreton L, Milcent R, Burstein C. Inhibition of monoamine oxidase types A and by by 2-aryl-4H-1,3,4-oxadiazine-5(6H)-one derivatives.Eur J Med Chem 1988; 23: 441–451.

    Google Scholar 

  18. Mazous F, Lebreton L, Milcent R, Burstein C. 5-Aryl-1,3,4-oxadiazol-2(3H)-one derivatives and sulfur analogoues as new selective and competitive monoamine oxidase type B inhibitors.Eur J Med Chem 1990; 25: 659–671.

    Google Scholar 

  19. Landais P, Crouzel C. A new synthesis of carbon-11 labelled phosgene.Appl Radiat Isot 1987; 38: 297–300.

    Google Scholar 

  20. Blanchard J. Evaluation of the relative efficacy of various techniques for deproteinizing plasma samples prior to high performance liquid chromatographic analysis.J Chromatogr 1981; 226: 455–460.

    Google Scholar 

  21. Riche D, Hantraye P, Guibert B, Naquet R, Loch C, Maziére B, Maziére M. Anatomical atlas of the baboon's brain in the orbitomeatal plane used in experimental positron emission tomography.Brain Res Bull 1988; 20: 283.

    Google Scholar 

  22. Saura J, Kettler R, Da Prada M, Richards JG. Quantitative enzyme radioautography with3H-Ro 41-1049 and3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain.J Neurosci 1992; 12: 1977–1999.

    Google Scholar 

  23. Willoughby J, Glover V, Sandler M. Histochemical localisation of monoamine oxidase A and B in rat brain.J Neural Transm 1988; 74: 29–42.

    Google Scholar 

  24. Levitt P, Pintar JE, Breakefield XO. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons.Proc Natl Acad Sci USA 1982; 79: 6385–6389.

    Google Scholar 

  25. Kalaria RN, Harik SI. Blood-brain barrier monoamine oxidase: enzyme characterization in cerebral microvessels and other tissues from six mammalian species, including human.J Neurochem 1987; 49: 856–864.

    Google Scholar 

  26. Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW. Distinct monoamine oxidase A and B populations in primate brain.Science 1985; 230: 181–183

    Google Scholar 

  27. Delforge J, Janier M, Syrota A, Crouzel C, Vallois J-M, Cayla J, Lancon J-P, Mazoyer BM. Noninvasive quantification of muscarinic receptors in vivo with positron emission tomography in the dog heart.Circulation 1990; 82: 1494–1504.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service Hospitalier Frédéric Joliot, DRIPP, CEA, 4, Place du Général Leclerc, F-91406, Orsay Cedex, France

    Suzanne Bernard, Chantal Fuseau & Christian Crouzel

  2. Laboratoire de Chimie Organique Médicale, Unité de Recherche Chimie et Pharmacologie, Faculté de Médecine Xavier Bichat, Université Paris 7, 16, rue Henri Huchard, BP 416, F-75870, Paris Cedex 18, France

    Suzanne Bernard & René Milcent

  3. Service Hospitalier Frédéric Joliot, CNRS URA 1285, CEA, F-91406, Orsay, France

    Lorenz Schmid

Authors
  1. Suzanne Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chantal Fuseau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lorenz Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. René Milcent
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christian Crouzel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bernard, S., Fuseau, C., Schmid, L. et al. Synthesis and in vivo studies of a specific monoamine oxidase B inhibitor: 5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)-1,3,4-oxadiazol-[11C]-2(3H)-one. Eur J Nucl Med 23, 150–156 (1996). https://doi.org/10.1007/BF01731838

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01731838

Key words

Search

Navigation